Literature DB >> 18403271

Treatment of patients with complex regional pain syndrome type I with mannitol: a prospective, randomized, placebo-controlled, double-blinded study.

Roberto S Perez1, Elien Pragt, José Geurts, Wouter W Zuurmond, Jaap Patijn, Maarten van Kleef.   

Abstract

UNLABELLED: To assess the effects of intravenous administration of the free radical scavenger mannitol 10% on complaints associated with complex regional pain syndrome Type I (CRPS I), a randomized, placebo-controlled, double-blinded trial was performed. Forty-one CRPS I patients according to the Bruehl et al diagnostic criteria, were included in 2 outpatient pain clinics of 2 university medical centers and randomly assigned to receive either 10% mannitol iv in 1 L 0.9% NaCL in 4 hours for 5 consecutive days or equal volumes of 0.9% NaCL (placebo). Patients in both groups received physical therapy according to protocol and rescue pain medication if required. Complaints on impairment and disability level and quality of life were assessed up to 9 weeks after baseline, with primary measurement points at 2, 6, and 9 weeks. Monitoring of pain using the visual analogue scale took place continuously during the course of the trial. Except for a significant improvement on a subscale of the Jebsen-Taylor hand function test, no significant differences were found between mannitol and placebo treatment. Changes in both groups in the course of the trial were small and clinically irrelevant on all measurement indices. We conclude that intravenous administration of 10% mannitol is not more effective than placebo in reducing complaints for CRPS I patients and provides no addition to already-established interventions for CRPS I. Whether 10% mannitol can provide beneficial effects for subgroups of CRPS I patients with a pathophysiological profile more closely fitting the presumed mode of action for this intervention remains to be established. PERSPECTIVE: This article addresses the efficacy of the intravenous administration of the free radical scavenger mannitol for treatment of CRPS type 1. This intervention is not more effective than placebo in reducing complaints for CRPS I patients and provides no addition to already-established interventions for CRPS I.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403271     DOI: 10.1016/j.jpain.2008.02.005

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  6 in total

1.  Mannitol improves cerebral oxygen content and postoperative recovery after prolonged retroperitoneal laparoscopy.

Authors:  Xiang Zhou; Ming-chun Wu; Yan-lin Wang; Xiao-yang Song; Na-jia Ling; Jun-zhe Yang; Dan Zhang; Bi-xi Li; Jun Tao
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

Review 2.  Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials.

Authors:  Andrea L Nicol; Robert W Hurley; Honorio T Benzon
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

3.  Evidence based guidelines for complex regional pain syndrome type 1.

Authors:  Roberto S Perez; Paul E Zollinger; Pieter U Dijkstra; Ilona L Thomassen-Hilgersom; Wouter W Zuurmond; Kitty Cj Rosenbrand; Jan H Geertzen
Journal:  BMC Neurol       Date:  2010-03-31       Impact factor: 2.474

4.  The Therapeutic Effect of Vitamin C in an Animal Model of Complex Regional Pain Syndrome Produced by Prolonged Hindpaw Ischemia-Reperfusion in Rats.

Authors:  Jae Hun Kim; Yong Chul Kim; Francis Sahngun Nahm; Pyung Bok Lee
Journal:  Int J Med Sci       Date:  2017-01-15       Impact factor: 3.738

Review 5.  Complex regional pain syndrome: a recent update.

Authors:  En Lin Goh; Swathikan Chidambaram; Daqing Ma
Journal:  Burns Trauma       Date:  2017-01-19

Review 6.  Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management.

Authors:  George Groeneweg; Frank J P M Huygen; Terence J Coderre; Freek J Zijlstra
Journal:  BMC Musculoskelet Disord       Date:  2009-09-23       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.